Article
Roswell Park Physicians Asked to Share Expertise in National Leadership Roles
Author(s):
In Partnership With:
Two Roswell Park Comprehensive Cancer Center physicians are expanding their leadership roles across the United States and abroad with recent appointments in their respective fields of specialty.
Two Roswell Park Comprehensive Cancer Center physicians are expanding their leadership roles across the United States and abroad with recent appointments in their respective fields of specialty.
Roswell Park's Chief of Lymphoma, Francisco Hernandez-Ilizaliturri, MD, was nominated by his peers as Co-Chair of ClinicalPath’s Oncology Pathways Lymphoma Committee. ClinicalPath, formerly ViaOncology, is a cancer-care management and decision-support tool produced by Elsevier. Their pathways, a tool used by medical professionals to help guide decisions about the best treatment plan for each individual patient, span the continuum of cancer care and incorporate National Comprehensive Cancer Network (NCCN) guidelines, of which Roswell Park is a member institution.
Dr. Hernandez-Ilizaliturri's research focuses on management of lymphoma malignancies and overcoming resistance to treatment. He completed fellowships in medical oncology and immunology at Roswell Park and residency at the University at Buffalo.
Oscar Colegio, MD, PhD, the Lawrence P & Joan Castellani Family Endowed Chair in Dermatology at Roswell Park, has been elected President of the International Immunosuppression and Transplant Skin Cancer Collaborative (ITSCC). This organization, comprised of more than 500 physicians, surgeons and scientists dedicated to understanding skin cancer in organ transplant recipients. In immunosuppressed individuals, the body provides less natural surveillance for cancer cells, which may then allow these cells to start growing, unchecked, particularly in the skin. Dr. Colegio started his two-year term in this role in mid-March.
Dr. Colegio, who joined Roswell Park in 2018 from the Yale School of Medicine, specializes in cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, immunology, immunodeficiency-associated skin cancers and solid organ transplantation. He holds doctoral and medical degrees from Yale University in New Haven, Connecticut.
